Compare AGEN & ACRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | ACRE |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2M | 245.8M |
| IPO Year | 1999 | 2011 |
| Metric | AGEN | ACRE |
|---|---|---|
| Price | $5.00 | $4.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $14.50 | $5.38 |
| AVG Volume (30 Days) | ★ 8.0M | 475.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.58% |
| EPS Growth | ★ 100.00 | 26.17 |
| EPS | 1.02 | ★ 1.35 |
| Revenue | $42,877,086.00 | ★ $54,833,000.00 |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | N/A | $16.28 |
| P/E Ratio | $4.95 | ★ $3.47 |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $4.05 |
| 52 Week High | $8.70 | $5.89 |
| Indicator | AGEN | ACRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 50.84 |
| Support Level | $3.16 | $4.33 |
| Resistance Level | N/A | $4.73 |
| Average True Range (ATR) | 0.63 | 0.13 |
| MACD | 0.21 | 0.04 |
| Stochastic Oscillator | 35.63 | 77.33 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.